APA (7th ed.) Citation

Yang, C., Kim, C., Kwak, K., Kang, K., Park, Y., Kim, B. S., . . . Choi, Y. S. (2026). Real-World Experience of Weekly Carfilzomib in Combination with Cyclophosphamide and Dexamethasone in Multiple Myeloma Relapsed/Refractory to Bortezomib and Lenalidomide. Cancer Research & Treatment, 58(1), 320. https://doi.org/10.4143/crt.2025.418

Chicago Style (17th ed.) Citation

Yang, Cheongin, Changgon Kim, Kunye Kwak, Ka-Won Kang, Yong Park, Byung Soo Kim, Seong Hyun Jeong, Joon Seong Park, and Yoon Seok Choi. "Real-World Experience of Weekly Carfilzomib in Combination with Cyclophosphamide and Dexamethasone in Multiple Myeloma Relapsed/Refractory to Bortezomib and Lenalidomide." Cancer Research & Treatment 58, no. 1 (2026): 320. https://doi.org/10.4143/crt.2025.418.

MLA (9th ed.) Citation

Yang, Cheongin, et al. "Real-World Experience of Weekly Carfilzomib in Combination with Cyclophosphamide and Dexamethasone in Multiple Myeloma Relapsed/Refractory to Bortezomib and Lenalidomide." Cancer Research & Treatment, vol. 58, no. 1, 2026, p. 320, https://doi.org/10.4143/crt.2025.418.